JP2020537526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537526A5 JP2020537526A5 JP2020521363A JP2020521363A JP2020537526A5 JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5 JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020521363 A JP2020521363 A JP 2020521363A JP 2020537526 A5 JP2020537526 A5 JP 2020537526A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus vector
- expression cassette
- vector according
- region
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000701161 unidentified adenovirus Species 0.000 claims description 40
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 241000282693 Cercopithecidae Species 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 2
- 230000000890 antigenic effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020004999 messenger RNA Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 241001217856 Chimpanzee adenovirus Species 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572951P | 2017-10-16 | 2017-10-16 | |
| US62/572,951 | 2017-10-16 | ||
| PCT/EP2018/078212 WO2019076882A1 (en) | 2017-10-16 | 2018-10-16 | ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537526A JP2020537526A (ja) | 2020-12-24 |
| JP2020537526A5 true JP2020537526A5 (enExample) | 2021-11-25 |
Family
ID=63896162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521363A Withdrawn JP2020537526A (ja) | 2017-10-16 | 2018-10-16 | Ｒｓｖ抗原性タンパク質又はその断片をコードする２つの発現カセットを有するアデノウイルスベクター |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11859199B2 (enExample) |
| EP (1) | EP3697919A1 (enExample) |
| JP (1) | JP2020537526A (enExample) |
| CN (1) | CN111527213A (enExample) |
| BR (1) | BR112020007008A2 (enExample) |
| CA (1) | CA3079048A1 (enExample) |
| MX (1) | MX2020003748A (enExample) |
| WO (1) | WO2019076882A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4177347A4 (en) * | 2020-07-06 | 2024-12-18 | Jiaxing Anyu Biotechnology Co., Ltd | NOVEL CHIMPANZEE ADENOVIRUS VECTOR, PRODUCTION PROCESS AND USE THEREOF |
| KR102399308B1 (ko) * | 2020-11-10 | 2022-05-20 | 주식회사 비엘 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| WO2022102894A1 (ko) * | 2020-11-10 | 2022-05-19 | 주식회사 바이오리더스 | 코로나바이러스의 스파이크 단백질 및 뉴클레오캡시드 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
| KR102882279B1 (ko) * | 2022-05-09 | 2025-11-10 | 주식회사 모아라이프플러스 | 코로나바이러스의 스파이크 단백질, 뉴클레오캡시드 단백질 및 PgsA 단백질을 동시발현하는 복제불능 아데노바이러스를 이용한 코로나바이러스 백신 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005015728A1 (de) | 2005-04-06 | 2006-10-12 | Robert Bosch Gmbh | Verbindungsvorrichtung für einen Antrieb sowie Verfahren zur Herstellung einer Verbindungsvorrichtung |
| WO2008095027A2 (en) * | 2007-01-30 | 2008-08-07 | Cedars-Sinai Medical Center | Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene |
| WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
| AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| JP6091435B2 (ja) | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| CA2890034A1 (en) | 2012-11-16 | 2014-05-22 | Allergan, Inc. | Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations |
| CA2951430A1 (en) * | 2014-06-13 | 2015-12-17 | Glaxosmithkline Biologicals Sa | Immunogenic combinations |
| JP6983665B2 (ja) | 2015-06-12 | 2021-12-17 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | アデノウイルスポリヌクレオチド及びポリペプチド |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2018
- 2018-10-16 BR BR112020007008-4A patent/BR112020007008A2/pt not_active IP Right Cessation
- 2018-10-16 US US16/756,380 patent/US11859199B2/en active Active
- 2018-10-16 MX MX2020003748A patent/MX2020003748A/es unknown
- 2018-10-16 CA CA3079048A patent/CA3079048A1/en not_active Abandoned
- 2018-10-16 WO PCT/EP2018/078212 patent/WO2019076882A1/en not_active Ceased
- 2018-10-16 CN CN201880081339.5A patent/CN111527213A/zh not_active Withdrawn
- 2018-10-16 EP EP18789095.9A patent/EP3697919A1/en not_active Withdrawn
- 2018-10-16 JP JP2020521363A patent/JP2020537526A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Das et al. | Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review | |
| Mezhenskaya et al. | M2e-based universal influenza vaccines: a historical overview and new approaches to development | |
| JP2020537526A5 (enExample) | ||
| ES2517869T3 (es) | Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos | |
| JP2017515508A5 (enExample) | ||
| JP2008530245A5 (enExample) | ||
| JP2016513115A5 (enExample) | ||
| JP2019501208A5 (enExample) | ||
| JP2017502662A5 (enExample) | ||
| EP2440244B1 (en) | Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens | |
| JP2020537525A5 (enExample) | ||
| JP2021500880A5 (enExample) | ||
| US11859199B2 (en) | Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof | |
| ES3056141T3 (en) | Simian adenoviral vectors with two expression cassettes | |
| JP2012517239A5 (enExample) | ||
| JP4797149B2 (ja) | インフルエンザウイルスに対するベクターワクチン | |
| WO2023217189A2 (zh) | 一种呼吸道合胞病毒腺病毒载体疫苗及其制备方法和应用 | |
| JP2025504364A (ja) | 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン | |
| Moskvicheva et al. | Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer | |
| Kim et al. | Preparedness for Future Pandemics Using a Highly Effective Recombinant Vesicular Stomatitis Virus-Based Vaccine Platform Technology: Strategies for Developing Superior Vaccines. Medical Research Archives,[online] 13 (12) | |
| pertussis Novavax et al. | Covid-19 Vaccines: Several technologies at work | |
| Tchilian et al. | Harnessing Local Immunity for an Effective Universal Swine In? uenza Vaccine. | |
| Sallberg et al. | 714. Attenuation of V-or C-Defective Measles Viruses: Infection Control by the Inflammatory and Interferon Responses of Rhesus Monkeys | |
| CN111328344A (zh) | 增强的启动子 | |
| RU2007108290A (ru) | Рекомбинантные векторы на основе "живого" вируса оспы домашней птицы и их применение в фармацевтических композициях против вируса гепатита с |